# V1 Empirics Check — qwen/qwen3.5-397b-a17b (Variant C)

**Model:** qwen/qwen3.5-397b-a17b
**Variant:** C
**Date:** 2026-03-13T17:59:47.099353

---

# Review: Digital Prescriptions, Analog Deaths

## 1. Idea Fidelity
The paper largely adheres to the original manifest's core identification strategy and research question. It successfully implements the staggered difference-in-differences (DiD) design using Callaway--Sant'Anna estimators and maintains the proposed mechanism test via opioid subtype decomposition (T40.2 vs. T40.4 vs. T40.1). However, there are two notable deviations from the manifest that impact econometric power. First, the manifest proposed using state-month data (CDC VSRR), but the paper aggregates this to state-year observations using 12-month rolling counts extracted in December. This significantly reduces the variation available for identification. Second, the sample period ends in 2023 rather than the proposed 2024, likely due to data availability lags, though this should be explicitly justified. Finally, while the manifest promised an event study, **Table 3 in the provided LaTeX source is empty**, representing a critical execution failure relative to the proposed design.

## 2. Summary
This paper evaluates the causal impact of state-level Electronic Prescribing for Controlled Substances (EPCS) mandates on opioid overdose mortality using data from 2015 to 2023. Employing a staggered DiD design with 31 treated states, the author finds no statistically significant evidence that EPCS mandates reduced prescription opioid, synthetic opioid, or heroin mortality. The results suggest that digitizing prescription infrastructure has failed to curb mortality, likely because the opioid crisis has shifted decisively toward illicit fentanyl markets outside the regulatory reach of prescribing mandates.

## 3. Essential Points
The authors must address the following three issues before this paper can be considered for publication:

1.  **Statistical Power and Interpretation of Nulls:** The minimum detectable effect (MDE) is approximately 50% of the mean prescription opioid death rate. Claiming that mandates "fail to curb" the crisis is too strong when the confidence intervals allow for reductions of up to 28% (as noted in the abstract) or even larger in some specifications. An imprecise null is not evidence of zero effect; it is evidence of insufficient precision to detect clinically meaningful changes. The language must be tempered to reflect this uncertainty.
2.  **Data Aggregation and Serial Correlation:** The decision to aggregate monthly CDC VSRR data into annual observations throws away substantial identifying variation. Furthermore, using 12-month rolling counts extracted annually introduces mechanical serial correlation that state-level clustering may not fully absorb. With only 51 clusters (and effectively fewer due to staggered timing), standard errors are likely understated, or conversely, the loss of monthly variation renders the standard errors too large to be informative.
3.  **Missing Event Study Evidence:** Table 3 (Event Study) is empty in the current draft. For a staggered DiD design, visual or tabular evidence of parallel pre-trends is non-negotiable. Without coefficients for $e < 0$, the reader cannot verify the identifying assumption that treated and control states were on parallel mortality trajectories prior to mandate adoption.

## 4. Suggestions
The following recommendations are intended to strengthen the econometric rigor and policy relevance of the paper. While not all are strictly required for identification, addressing them will significantly improve the manuscript's contribution to the literature.

**Recover Monthly Variation**
The most significant econometric limitation in the current draft is the aggregation to state-year data. The CDC VSRR data is available at the state-month level, as noted in your own manifest. Aggregating to annual data reduces your sample size from ~5,500 state-months to ~459 state-years. In DiD designs, power is driven by the number of treatment switches and the frequency of observation. By moving back to monthly data, you would increase the degrees of freedom substantially.
*   *Action:* Re-estimate the main specifications using state-month panels.
*   *Inference:* When using monthly data, you must adjust standard errors for serial correlation. State-clustered SEs are standard, but given the high persistence of overdose rates, consider blocking the bootstrap by state or using Conley spatial standard errors to ensure robustness. If the null result holds with monthly data, the finding is far more robust.

**Refine the "Null" Narrative**
Econometrically, you cannot accept the null hypothesis; you can only fail to reject it. Given the MDE discussion in Section 5, you know that your study is underpowered to detect modest but policy-relevant effects (e.g., a 10% reduction in prescription deaths).
*   *Action:* Reframe the conclusion. Instead of stating mandates "fail to curb" the crisis, state that there is "no detectable evidence" of an effect large enough to alter the trajectory of the epidemic.
*   *Action:* Include a power curve or a figure showing the range of effect sizes ruled out by your confidence intervals. This allows policymakers to see exactly what magnitudes are inconsistent with your data. For instance, if you can rule out a 40% reduction but not a 10% reduction, say that explicitly.

**Address Confounding Policies (The "Bundle" Problem)**
You acknowledge in Section 4 that EPCS mandates often coincide with PDMP enhancements and prescribing limits. This is a classic omitted variable bias threat in policy bundles. If PDMPs became stricter simultaneously, your coefficient captures the joint effect.
*   *Action:* Include controls for PDMP stringency scores (e.g., from the PDMP Center of Excellence) if available at the state-year level.
*   *Action:* Alternatively, lean harder into the mechanism test. If PDMPs affect all opioids but EPCS affects only prescription opioids, your decomposition helps. However, since you find nulls everywhere, this is less helpful. A better approach might be to interact EPCS adoption with baseline prescribing rates. If EPCS works, it should have larger effects in states with historically high prescribing volumes. A null even in high-prescribing states would strengthen the "too late" narrative.

**Fix the Event Study and Visualization**
The empty Table 3 is a critical omission. In modern DiD literature (post-Callaway--Sant'Anna, Sun--Abraham), the event study plot is often more informative than the aggregate ATT table.
*   *Action:* Populate Table 3 with coefficients and standard errors for leads and lags.
*   *Action:* Ideally, replace or supplement Table 3 with a figure plotting the event study coefficients with confidence intervals. Visual inspection of pre-trends is standard practice in *AER: Insights*.
*   *Action:* Ensure the reference period (e.g., $e = -1$) is clearly defined in the notes.

**Clarify Data Construction**
The use of "12-month rolling counts... extract for December" is slightly confusing. If you take the rolling count ending in December 2015, that is effectively the calendar year 2015. If you take the rolling count ending in December 2016, that is calendar year 2016.
*   *Action:* Clarify in the Data section whether these are non-overlapping annual totals or if there is any overlap in the construction. If they are non-overlapping annual totals, describe them as such rather than emphasizing the "rolling" nature, which implies overlap that might complicate error structures.
*   *Action:* Justify the 2023 end date. If VSRR data for 2024 was unavailable at the time of analysis, state this clearly to manage expectations about the "2024" date in the manifest.

**Standardized Effect Sizes**
Table 4 includes a "Classification" column (e.g., "Moderate positive") based on arbitrary thresholds (e.g., 0.05 to 0.15). This adds little value and risks appearing subjective.
*   *Action:* Remove the classification column. Report the standardized effect size and its confidence interval, but let the reader interpret the magnitude. Econometric reviews generally prefer raw coefficients in the main text with standardized sizes in an appendix, if at all.

**Policy Contextualization**
The discussion on the "Fentanyl Transition" is the strongest part of the paper. To make this more compelling:
*   *Action:* Add a figure showing the cross-over point where synthetic opioid deaths surpassed prescription opioid deaths nationally and within your sample states. Align this timeline with the EPCS adoption waves. If most states adopted mandates *after* the cross-over point, this visually reinforces your "too late" hypothesis.
*   *Action:* Discuss the cost side briefly. You mention states invested in infrastructure. If you can find even rough estimates of implementation costs (e.g., from state legislative fiscal notes), a simple cost-benefit comment
